F-1/A: Innocan Pharma Launches IPO to Fund CBD Drug Development

Innocan Pharma Corporation is launching an initial public offering of 2.35 million units on the NYSE American to raise approximately $10.89 million, primarily to advance its preclinical CBD-loaded liposome platform for chronic pain management.

Summary

• Innocan Pharma Corporation is undertaking an Initial Public Offering (IPO) of 2,350,000 units, each consisting of one common share and one warrant to purchase one common share, with an anticipated price range of $5.00 to $6.00 per unit.
• The company expects to raise approximately $10.89 million in net proceeds from this offering, which will be primarily allocated to research and development (R&D) for its LPT-CBD project ($6.5 million for human applications, $2.5 million for veterinary applications) and $1 million for U.S. marketing and sales.
• Innocan Pharma operates in two main segments: Pharmaceuticals, focusing on innovative drug delivery technologies for human and animal health using its synthetic Cannabidiol-loaded Liposome injection Platform (LPT-CBD), and Consumer Wellness, which develops and markets self-care and hemp-derived CBD beauty products.
• The LPT-CBD platform is in late pre-clinical development, with a successful pre-IND meeting held with the FDA, structuring the development plan towards an Investigational New Drug (IND) submission for a Phase 1a study.
• The company reported revenues of $21,624,000 for the nine months ended September 30, 2025, a decrease from $24,036,000 in the same period of 2024, attributed to challenging market conditions and global trade tariffs.
• Net loss for the nine months ended September 30, 2025, increased to $2,196,000, compared to a net loss of $214,000 for the same period in 2024, primarily due to decreased revenues and increased financial expenses.
• As of September 30, 2025, the company had an accumulated deficit of $38,027,000, and its financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• A 65-for-1 reverse share split of common shares was effected on September 5, 2025, and all share and per-share data in the prospectus have been retroactively restated to reflect this split.
• The company has applied to list its common shares and warrants on the NYSE American under the symbols INNP and INNPW, respectively, with current trading on the CSE (INNO), OTCQB (INNPD), and FSE (IP4).

Sentiment

Score: 4

Explanation: The company presents promising preclinical data for its LPT-CBD platform and operates in high-growth markets. However, it is still in the early pre-clinical stage for its pharmaceutical products, has a history of significant net losses, and faces substantial doubt about its ability to continue as a going concern. The recent interim financial results show a decline in revenue and an increased net loss, indicating ongoing financial challenges despite the capital raise.

Positives

• The LPT-CBD injectable platform shows promise in pre-clinical research for both human and animal chronic pain management, offering a sustained release of synthetic cannabidiol as a non-opioid alternative.
• A successful pre-IND meeting with the FDA has structured the development plan for LPT-CBD towards an IND submission, with the FDA acknowledging the potential for a 505(b)(2) abbreviated pathway.
• The company possesses a robust intellectual property portfolio with 31 published patents (granted and pending) across eight families, enhancing its competitive position.
• The Consumer Wellness segment, particularly through its B.I. Sky joint venture, has demonstrated historical revenue growth, with 2024 revenues increasing by $15.78 million to $29.437 million compared to 2023.
• The global pain management market is projected to grow to $109 billion by 2032 (CAGR 4.5%), and the veterinary pain management market to $2.20 billion by 2029 (CAGR 5.91%), indicating substantial market opportunities.
• The beauty and personal care market is projected to reach $693 billion by 2031 (CAGR 4.35%), with the online segment growing even faster (CAGR 11.5%), providing a strong growth avenue for the Consumer Wellness segment.
• Preclinical studies of LPT-CBD in various animal models (mice, dogs, minipigs, goats) have demonstrated long-lasting analgesic effects, high CBD bioavailability, and favorable tolerability with minimal side effects.
• The company's wellness segment boasts strong operational metrics, including over 5,100 units sold per day, a 0.01% return rate, and an 87.4% customer return rate within 30 days.

Negatives

• The company is a pre-clinical stage pharmaceutical tech company and has never generated revenue from LPT-CBD product sales in its Pharmaceuticals segment, anticipating significant losses until commercialization.
• A history of net losses has resulted in an accumulated deficit of $38,027,000 as of September 30, 2025, and the financial statements include an explanatory paragraph regarding substantial doubt about the ability to continue as a going concern.
• Net loss for the nine months ended September 30, 2025, significantly increased to $2,196,000 from $214,000 in the same period of 2024, driven by decreased revenues and increased financial expenses.
• Revenues for the nine months ended September 30, 2025, decreased by 10% to $21,624,000 compared to $24,036,000 in the prior year, reflecting challenging market conditions and global trade tariffs.
• The company expects to need additional funding beyond the IPO proceeds, which may not be available on acceptable terms or at all, potentially requiring curtailment, delay, or discontinuation of operations.
• The 505(b)(2) regulatory pathway, while streamlined, does not guarantee marketing approval, and if the FDA determines it's not applicable, additional non-clinical studies would be required, increasing time, cost, and risk.
• The company's reliance on third parties for clinical trials, research, preclinical testing, and manufacturing introduces risks of unsatisfactory performance, delays, or increased costs.
• As a foreign private issuer, the company will follow certain home country corporate governance practices instead of NYSE American rules, potentially offering less protection to U.S. investors.

Risks

• We are a pre-clinical stage company and anticipate significant losses until we commercialize our pharmaceutical products.
• We may not achieve or maintain sufficient working capital to meet future obligations.
• We have never generated revenue from LPT CBD product sales in our Pharmaceuticals segment.
• We expect to need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding may require us to curtail, delay, or discontinue operations.
• We have a history of net loss, and as of September 30, 2025, December 31, 2024 and December 31, 2023, we had an accumulated deficit of $38,027,000, $34,908,000 and $33,074,000, respectively. Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
• Our pharmaceutical product candidates are in preclinical development. We cannot assure that any product candidates will receive regulatory approval, necessary for commercialization.
• We may not receive, or may be delayed in receiving, necessary approvals for our CBD-loaded liposome platform (LPT-CBD) or future products, affecting our ability to grow.
• If the FDAs Section 505(b)(2) pathway for certain of our drug candidates is not available, the development of certain of our drug candidates will likely take significantly longer, cost significantly more and entail significantly greater complexity and risk than currently anticipated, and, in any case may not be successful.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain regulatory clearances or approvals, or to manufacture, market, or distribute products after approval.
• Clinical and preclinical development is uncertain. Current pre-clinical programs may experience delays or may never advance to clinical trials, affecting our ability to obtain regulatory approvals or commercialize these programs.
• Future clinical trials may be delayed, certain programs may never advance, or may be more costly, affecting our ability to fund operations and impacting our business.
• Clinical trials may fail to show safety and effectiveness, preventing regulatory approval and commercialization.
• Even with completed preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain, potentially preventing approvals.
• Early-stage clinical trial results may not predict future results; initial data may not reflect final or later-stage trial outcomes.
• Research and development of central nervous system, or CNS, -targeting drugs is difficult, making it hard to predict why a drug works for some patients but not others.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development.
• Product candidates may have side effects or safety risks, delaying or halting development, preventing approval, or limiting commercial potential.
• Approved products may fail to achieve market acceptance, affecting revenue and profitability.
• Clinical trials conducted outside the U.S. may not be accepted by FDA, EMA, or other regulatory authorities.
• Failure to obtain regulatory approval in any jurisdiction could substantially harm our business.
• Complex pharmaceutical product candidates may face manufacturing problems, delaying development or commercialization.
• We may not use expedited development or regulatory review processes for breakthrough or fast track designated products.
• Approved products will face ongoing regulatory obligations and review, incurring additional expenses and potential penalties for non-compliance.
• If the market opportunities for our pharmaceutical product candidates are smaller than we believe, our revenue may be adversely affected. Our ability to identify patients and acquire a significant market share is necessary for profitability and growth.
• The commercial success of any future pharmaceutical products will depend on market acceptance by physicians, healthcare payers, patients, and the medical community.
• If we are unable to establish sales and marketing capabilities or enter agreements with third parties to sell and market any product candidates we develop, we may not successfully commercialize those product candidates.
• We face intense competition and rapid technological change, and our competitors may discover, develop, or commercialize therapies that are similar, more advanced, or more effective than ours.
• The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.
• Failure to comply with controlled substance legislation could restrict or harm our ability to develop and commercialize products.
• Cannabis remains illegal under U.S. federal law, and changes in enforcement priorities could render operations unprofitable or prohibit them.
• The cannabis industry and regulations continue to develop, and changes that differ from our expectations or are adverse to us may impact our business and operations.
• Failure to comply with various regulations could prevent us from carrying on our business and we may incur costs.
• We may become involved in disputes and legal or regulatory proceedings that, if adversely decided or settled, could materially affect our business, financial condition, and results of operations.
• We may be required to recall products and face product liability claims, resulting in unexpected costs and damaging our reputation.
• If our products are not manufactured in compliance with regulations, do not meet quality standards, or result in adverse health effects, it could cause reputational harm, remedial costs, or regulatory enforcement.
• New laws, regulations, enforcement trends, or changes in regulations governing the introduction, marketing, and sale of our products could harm our business.
• Our facilities and those of third-party manufacturers are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FDCA, and FDA regulations.
• Government regulations and private party actions relating to marketing may restrict, our ability to sell products and harm our business, financial condition, and results of operations.
• Government regulation of the Internet and e-commerce is evolving, and unfavorable changes or failure to comply could substantially harm our business, financial condition, and results of operations.
• Healthcare legislation aimed at reducing costs may have a material adverse effect on our business.
• Governments outside the United States may impose strict price controls, adversely affecting our revenues.
• We may seek additional collaborations and may not be successful in maintaining or entering new ones. Even if successful, we may not realize the benefits.
• We rely on third parties for clinical trials, research, and preclinical testing. These third parties may not perform satisfactorily.
• We have no sales, distribution, or marketing experience and may invest significant resources to establish these capabilities. Failure to do so or to enter agreements with third parties may prevent us from generating revenues.
• If we are unable to obtain and maintain effective intellectual property rights, we may not compete effectively.
• We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.
• We need to expand our organization and may have difficulties managing growth, disrupting operations.
• We may not succeed in identifying, discovering, or licensing additional product candidates.
• Employment laws may prevent us from enforcing non-compete covenants, allowing competitors to benefit from former employees expertise.
• Our success depends on retaining executive officers and attracting, retaining, and motivating qualified personnel.
• Increasing scrutiny of sustainability and ESG initiatives could increase costs or impact our business.
• Unfavorable economic and market conditions and financial institution developments may adversely affect our business, operating results, and growth rates.
• We may be classified as a passive foreign investment company, causing adverse tax consequences for U.S. shareholders.
• As a foreign private issuer, we follow home country corporate governance practices and are not subject to certain U.S. securities laws and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation.
• As an emerging growth company, reduced disclosures may make us less attractive to investors.
• Recent initial public offerings of similar companies have experienced extreme volatility unrelated to performance. We may experience similar volatility, affecting the assessment of our shares value.
• Part of our operations are conducted in Israel. Conditions in Israel, including the recent conflict with Iran, attacks by Hamas and other terrorist organizations and Israels war against them, could materially and adversely affect our business.
• It may be difficult to enforce a U.S. judgment against us, our officers, and directors not in the U.S., or to assert U.S. securities laws claims or serve process on our officers and directors not in the U.S.
• We are governed by the corporate laws of Canada which in some cases have a different effect on shareholders than the corporate laws of the United States.
• Our business and operations might be adversely affected by security breaches, including cybersecurity incidents.
• Sales or significant short sales of our common shares, or the perception of such sales, could depress the market price and impair our ability to raise capital.
• If securities or industry analysts do not publish or cease publishing research or reports about us, or if they publish negative reports, our share price and trading volume could decline.

Future Outlook

Innocan Pharma plans to commence LPT-CBD scale-up activities approximately three months after the IPO, expected to take one year. Following this, a GLP-compliant single-injection preclinical safety study will be conducted, with final reporting anticipated within 6-8 months. An IND application will then be submitted to the FDA, with Phase 1a first-in-human studies commencing 30 days post-submission, estimated to take 6-8 months. Phase 1b studies are intended to begin immediately after Phase 1a approval and completion of a repeated-dose GLP safety study. The company also intends to submit an INAD application with the FDA-CVM during the second half of 2025 for veterinary applications. The wellness product portfolio will continue to expand, with ongoing efforts to track and comply with US regulations like MoCRA. Once key regulatory milestones are achieved for LPT-CBD, the company aims to engage pharmaceutical companies in licensing discussions for human and animal health applications.

Management Comments

• Committed to improving quality of life by addressing chronic pain in humans and animals through innovative therapeutic solutions.
• Believe that the LPT-CBD injectable drug product has demonstrated promise in pre-clinical research for both human and animal use by providing a sustained release of synthetic cannabidiol with significant bioavailability over time, as an alternative to traditional pain management therapies, including opioids.
• Believe that the robust intellectual property portfolio will enhance the competitive position and help establish a strong market presence.
• Believe that the experienced, mission-driven team enables the advancement of programs and effective response to market needs and regulatory demands.
• Believe that progressing along a defined regulatory support and pathways will position the company well in the market and on track to commercialization.
• Objective is to positively impact lives by addressing chronic pain in humans and animals, as well as promote wellness through innovative products.
• The company's business model is driven by a three-tiered strategy: Animal Health (licensing/partnerships, INAD application in 2H 2025), Human Health (licensing/partnerships, pending IND studies), and Wellness (marketing personal care/beauty products via multiple channels).
• Committed to bringing safer, effective alternatives to the market, transforming the landscape of chronic pain management and wellness.

Industry Context

The filing highlights the urgent need for alternative pain management solutions in the context of the global opioid crisis, which has strained healthcare systems and caused significant suffering, with opioids implicated in over 75% of U.S. drug overdose deaths. The global pain management market is projected to reach $109 billion by 2032, with chronic pain being a major contributor. The veterinary pain management market is also growing, driven by increased pet ownership and awareness of pet health needs. The beauty and personal care market is expanding, fueled by e-commerce and demand for anti-aging/skincare products. Innocan Pharma positions its LPT-CBD technology as a non-opioid alternative to address these market needs, while its wellness products cater to the broader self-care trend. The regulatory landscape for cannabis-derived products is evolving, with federal illegality in the U.S. for cannabis, but hemp-derived CBD products (like Innocan's wellness line) are subject to state and FDA oversight, including new regulations like MoCRA for cosmetics.

Comparison to Industry Standards

• LPT-CBD is being developed as a non-opioid alternative for chronic pain management, directly addressing the opioid crisis and the FDA's support for non-opioid pain treatments, such as Vertex Pharmaceuticals' recently approved non-opioid for acute pain.
• The company is pursuing the FDA's 505(b)(2) abbreviated pathway for LPT-CBD for human health, leveraging existing data from approved products like Epidiolex (Jazz Pharmaceuticals), a CBD oral drug approved for epilepsy. This strategy aims for a more efficient development process compared to a full NDA.
• Competitors in the cannabinoid pharmaceutical space include Jazz Pharmaceuticals (Epidiolex), AbbVie, Pfizer, Sanofi, Bristol-Myers Squibb (expanding patent portfolios in cannabinoid-based therapies), Zynerba Pharmaceuticals (transdermal CBD), Skye Bioscience (synthetic cannabinoid-derived molecules), Corbus Pharmaceuticals (synthetic cannabinoid for systemic sclerosis), RespireRx Pharmaceutical (dronabinol for OSA), Synendos Therapeutics (endocannabinoid modulators), and Inversago Pharma (peripheral cannabinoid receptor antagonist).
• Innocan's LPT-CBD technology, with its sustained-release injectable delivery, differentiates it from existing oral CBD formulations like Epidiolex and other traditional pain management therapies (steroids, opioids, NSAIDs) by offering high bioavailability and minimal side effects.
• The company's wellness segment competes in a highly competitive beauty and personal care market, aiming for market leadership through proprietary formulations, rigorous testing, and expertise in online marketplaces like Amazon, where many long-standing major players operate.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Tamar Innovest Limited, the company's largest shareholder and associated with director Ralph C.L Bossino, participated in private placements in August 2023 (17,391 units for $179,400) and a secured convertible debenture offering in March 2025 ($1,000,000 gross proceeds).
• A joint venture company, B.I. Sky Global Ltd., was established with Brandzon Co Ltd. (40% owned by Brandzon), a private Israeli company co-founded by Roni Kamhi, the company's Chief Operating Officer. Innocan holds 60% of B.I. Sky.
• The company extended an owner's loan of approximately $3,000,000 to B.I. Sky, bearing interest pursuant to Israeli Tax Ordinance and extended for repayment until the earlier of February 15, 2026, or an exit event of B.I. Sky. No principal or interest payments have been made to date.
• A loan of $14,291 extended to CEO Iris Bincovich on July 1, 2020, was non-interest-bearing and fully repaid by December 31, 2023.

Stakeholder Impact

• Shareholders: New investors will experience immediate dilution of $3.44 per common share. Existing shareholders will see an increase in net tangible book value of $0.59 per share. The IPO and future capital raises will dilute ownership interests. The stock price may experience extreme volatility, unrelated to underlying performance.
• Patients (Human & Animal): Potential for new non-opioid chronic pain management therapies through the LPT-CBD platform, aiming to improve quality of life and address risks associated with opioids.
• Employees: The company's growth and expansion plans, particularly in R&D and commercialization, could lead to increased hiring and opportunities. However, the early-stage nature and financial risks pose uncertainty regarding long-term stability.
• Customers (Consumer Wellness): Continued expansion of innovative self-care and beauty products, with a focus on quality and efficacy, aiming to build consumer trust and loyalty.
• Creditors: The 'going concern' explanatory paragraph in financial statements indicates potential challenges in meeting future obligations, which could affect creditors' confidence and terms of future financing.

Next Steps

• Complete LPT-CBD scale-up activities, expected to commence approximately three months after the IPO and take about one year.
• Conduct a Good Laboratory Practice (GLP)-compliant single-injection preclinical safety study for LPT-CBD, with final reporting anticipated within 6-8 months.
• Submit an Investigational New Drug (IND) application to the FDA for the initial Phase 1a study for human applications, including the clinical protocol and safety report.
• Commence Phase 1a first-in-human study 30 days post-IND submission, assuming no clinical hold, to collect pharmacokinetic (PK) and exposure data.
• Form a scientific bridge to Epidiolex to support a 505(b)(2) application to the FDA, running in parallel with Phase 1a studies (estimated 6-8 months).
• Begin Phase 1b studies immediately following approval of Phase 1a results and completion of a repeated-dose GLP safety study.
• Submit an INAD application with the FDA-CVM during the second half of 2025 to commence testing LPT-CBD product candidate in the U.S. for animal health applications.
• Engage pharmaceutical companies and industry leaders in licensing discussions for LPT-CBD once key regulatory milestones are achieved.
• Continue to expand the product portfolio in the Consumer Wellness segment with new developments and releases.
• Invest in product reach across digital commerce, online channels, and distribution partners for wellness products.
• Track and ensure ongoing compliance with US rules, including MoCRA, for personal care and beauty products.

Key Dates

Keywords

CBD, Cannabidiol, Liposome, LPT-CBD, Pain Management, Pharmaceutical, Biotech, IPO, NYSE American, Chronic Pain, Veterinary Medicine, Consumer Wellness, SEC Filing, F-1/A, Drug Delivery